DESIGN, DEVELOPMENT AND EVALUATION OF MOUTH DISSOLVING TABLETS OF TOFACITINIB CITRATE

Authors

  • MEGHANA RAYKAR Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India
  • MALARKODI VELRAJ Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42810

Keywords:

Mouth Dissolving, MDTs, Tofacitinib Citrate, Sodium Starch Glycolate, Ludiflash

Abstract

Objective: This study aims to Formulate Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate with the increase in bioavailability and patient compliance.

Methods: Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate were developed by full factorial design at 32 levels and prepared by direct compression method using superdintegrants like sodium starch glycolate, Ludiflash. The tablets were compressed into compacts on a 10 station tablet machine. The bulk drug was characterised by determining, MP, Solubility, pH and FTIR spectra.

Results: The weight variation, hardness and diameter, thickness, friability, drug content, wetting time, in vitro disintegration time and in vitro dissolution studies, and stability study, tablet thickness, weight variation and drug content post compression parameters remained consistent and reproducible. All the formulations showed, almost 100 percent of drug release within 75 min. Formulations F1, F2 and F3 were prepared with 5 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F1<F2<F3. Formulations F4, F5 and F6 were prepared with 10 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows %  release of drug in the order of F4<F5<F6. Formulations F7, F8 and F9 were prepared with 15 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows  % release of drug in the order of F7<F8<F9.

Conclusion: It is concluded that the amount of Superdisintegrants decreases disintegration time of tablets, decreases wetting time, increases the cumulative % drug release causes better absorption.

Downloads

Download data is not yet available.

References

Shyamala B, Narmada GY. Rapid dissolving tablets: A novel dosage form. The Indian Pharmacist. 2002;13(8):09-12.

International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1079-1091, Oct-Dec 2009.

Dr.Avani F. Amin Emerging Trends In The Development Of Orally Disintegrating Tablet Technology pharmainfo.net 01/26/2006.

Poreddy Srikanth Reddy, Penjuri Subhash Chandra Bose, Damineni Saritha, Vuppula Sruthi. Formulation and Evaluation of Colon Targeted Matrix Tablet Using Natural Tree Gums. Int J Pharm Pharma Sci 2018;10(9):92-97.

Meghawati R. Sandhya L. Borse, Manisha S. Junagade, Anil G. Jadha, Formulation and Evaluation of Mouth Dissolving Tablet of Amlodipine Besylate. Int Journal of Applied Pharm 2019;11(4):132-139.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.

Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913–921.

https://www.rxlist.com/xeljanz-drug.htm

British journal of clinical pharmacology. 2018 Jul 84(6):1136‐1145.

Ayman Askari, Abdulia Khalid Nouri, Hana Morrissey, Patrik A. Ball, Janus kinase enzyme (JAK) inhibitors and Rheumatoid Arthritis: A Review of the Literature. Int J Current Pharma Res 2019; 11(6):11-14.

Papp KA,Krueger JG,Feldmen SR, Langley RG, Thaci D, Torii H, Trying S, Wolk R,

Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and Safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J. Am. Aca. Dermatol. 2016’74(5):841.doi:10.1016/j.iaad. 2016.01.013. Epub 2016 Feb 19.

National Center for Biotechnology Information. Pub Chem Compound Summary for CID 9926791, Tofacitinib. https://pubchem.ncbi.nlm.nih.gov/compound/Tofacitinib. Accessed Aug.31,2021.

Ai, F. et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur. J. Pharm. Biopharm. 2011;79:552-558,2011.

https://aksci.com/item_detail.php?cat=X7518

https://go.drugbank.com/drugs/DB08895

www. Pharma.basf.com

Buket Aksu et al; optimisation of ondansetron orally disintegrating tabltets using artificial neural networks. Tropical J Pharma Res 2014;13(9):1374-1383.

Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.

Devrajan PV, Gore SP.Melt-in-mouth tablets: innovative oral drug delivery system. Express Pharm Pulse. 2000;7:16-6.

C. F. Lourenco, Formulation and Evaluation of Rizatriptan Benzoate mouth disintegrating tablets. Department of Pharmaceutics, Goa College of Pharmacy, 18th June Road, Panaji, Goa-403 001, India. Indian J Pharm Sci, 2010;72(1):79-85.

N.V. Thakariya, S.B. Ezhaya, Development and Validation of UV Spectrophotometric Method for the Estimation of Tofacitinib Citrate. Pharma Science Monitor. April-Jun 2017;8(2):401-408.

Flanagan, Mark Edward; Li, Zheng Jane, preparation of novel crystalline compound useful as inhibitors of protein kinases PCT Int. April, (3002), WO 2003048162 A120030612.

Mark E. Flanagan , Todd A. Blumenkopf , Discovery of CP-690, 550: A Potent and Selective Janus Kinase (JAK) inhibitor for the treatment of Autoimmune Diseases and organ Transplant Rejection, Journal of Medicinal Chemistry(2010), 3(24),8468-8484.

Dnyaneshwar HR, Wale KK, Sayyed SF, Chaudhari SR. Orodispersible film dosage form: a review. World J Pharm Res. 2014;3(5):1093-1111.

Srivastava SK, Verma R, Chandra V, Srivastava SP, Orally disintegrating tablets a dosage form that extends the market exclusivity and patent protection World J Pharm Pharm Sci. 2014;3(7):526-546.

Rao MR, Sonavane V, Kulkarni S, Magar M, Zope A, Karanjkar P. Design of transdermal patch of ketoprofen by full factorial design for treatment of rheumatoid arthritis. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2): 197-205.

Bala R, Khanna S, Pawar P. Polymers in fast disintegrating tablets : a review Asian J Pharm Cli Res. 2012;5(2):8-14.

Deshpande KB, Ganesh NS. Orodispersible tablets: an overview of formulation and technology. Int J Pharma Bio Sci. 2011;2(1):726.

Panchal DM, Tiwari A, Srivastava P. a review on orodispersible tablets: a novel formulation for oral drug delivery system and its future prospective Indo American J Pharm Res. 2013;3(5):4149.

Nilesh R. Bhosale, Nikita S. Kolte, Formulation Development and Evaluation of orally disintegrating tablet of Chlorpheneramine Maleate by Sublimation Technique. Int J Pharmacy Pharma Sci 2019;11(9):28-36.

Gupta A, Mishra AK, Gupta V, Bansal P, SinghR, Singh AK. Recent trends of fast dissolving tablet: an overview of formulation technology. Int J Pharm Bio Arch 2010;1(1):1-10.

Abdul Rahoem T.,Ranjeet Singh, Aishwarya Hiremath, Shashant Nayak N. Shweta Kamath K.S.Formulation and Comparative Evaluation of Ondansetron Hydrochloride Mouth Dissolving Tablets In India. Int J Pharm Pharmac Sci 2019;11(4):57-64.

Madan J, Sharma AK, Singh R. Fast dissolving tablets of Aloe vera gel. Trop J Pharm Res.2009;8(1):63-70.

Kaushik D, Dureja H, Saini TR. Formulation and evaluation of olanzapine mouth dissolving tablets by effervescent formulation approach. J Adv Pharm Tech Res. 2004;41(4):147-192.

Gaur K, Tyagi LK, Kori ML, Nema RK. Formulation and characterization of fast disintegrating tablet of Aceclofenac by using sublimation method. Int J Pharm Sci Drug Res. 2011;3(1):19-22.

Simone S, Peter CS. Fast dissolving tablets. Eur J Pharm Sci. 2002;15(3): 295-305.

Malke S, Shidhaye S, Kadam V. Novel melt granulation using sugars for Metoclopramide Hydrochloride orally disintegrating tablet. Asian J Pharm Clin Res 2009;2(1):8-72.

Furtado S, Deveswaran R, Bharath S, Basvraj BV, Abraham S, Madhavan V. Development and characterization of orodispersible tablets of Famotidine containing a subliming agent. Trop J Pharm Res. 2008;7(4):1185-89.

Jain CP, Naruka PS. Formulation and evaluation of fast dissolving tablets of Valsartan. Int J Pharm Pharm Sci. 2009;1(1):219-26.

Nagendrakumar D, Raju SA, Shirsand SB, Para MS. Design of fast dissolving Granisetron HCL tablets using novel co-processed superdisintegrants. Int J Pharm Sci Rev Res. 2010;1(1):58-62.

Shirwalkar AA, Jacob S, Joseph A, Srinivasan KK. Novel co-processed excipients of mannitol and microcrystalline cellulose for preparing fast dissolving tablet of Glipizide. Ind J Pharm Sci. 2010:633-39.

Radke RS, Jadhav JK, Chajeed MR. Formulation and evaluation of orodispersible tablets of Baclofen. Int J Chem Tech Res. 2009;1(3):517-21.

Published

02-11-2021

How to Cite

RAYKAR, M., & VELRAJ, M. (2021). DESIGN, DEVELOPMENT AND EVALUATION OF MOUTH DISSOLVING TABLETS OF TOFACITINIB CITRATE. International Journal of Applied Pharmaceutics, 14(1). https://doi.org/10.22159/ijap.2022v14i1.42810

Issue

Section

Original Article(s)